Eli Lilly prepares obesity efforts with future hope – goes down same path as Novo Nordisk

US Eli Lilly is testing its weight loss and glucose control drug candidate Tirzepatide, joining Novo Nordisk on the obesity market for the first time. The road to commercialization will look a lot like that of Novo Nordisk, says Eli Lilly executive.

Ever since Novo Nordisk entered the obesity market in 2015, its management and investors have hoped for another pharmaceutical firm to accompany it and help establishing and focusing on the market for relevant treatments.

"It's a challenge that we're actually the only company that's trying to create a market for the medical treatment of obesity," Novo Nordisk's Head of North America Operations and Executive Vice President Doug Langa has previously said.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs